指南与共识前列腺癌

美国预防服务工作组前列腺癌筛查新「C」级推荐草案

The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening.
指南 / 共识 · Eur Urol · 2017-05-20

美国预防服务工作组发布新草案,对55-69岁男性给出「C」级推荐,应告知筛查利弊并在其选择时提供前列腺特异性抗原检测;对≥70岁男性维持「D」级推荐,即不筛查。作者认为草案方向正确,但证据回顾仍不充分,导致利弊呈现有偏。

要点

  • 55-69岁男性:「C」级推荐,告知筛查利弊,若其选择则提供前列腺特异性抗原检测。
  • ≥70岁男性:维持「D」级推荐,即不筛查。
  • 作者认为证据回顾不充分,利弊呈现有偏,最终指南应与专家正式合作。

核心结论

  • 草案在让男性公平讨论筛查利弊方面取得实质进展,但证据回顾仍不充分,利弊呈现有偏。

研究设计与样本

  • 美国预防服务工作组发布的指南草案。

主要发现

  • 对55-69岁男性给出「C」级推荐,应告知筛查利弊并在其选择时提供前列腺特异性抗原检测。
  • 对≥70岁男性维持「D」级推荐,即不筛查。

关键数值与推荐

  • 55-69岁男性:「C」级推荐,告知利弊并可在其选择时提供前列腺特异性抗原检测。
  • ≥70岁男性:「D」级推荐,即不筛查。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 草案所依据的证据回顾仍不充分,导致筛查利弊的呈现有偏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The US Preventive Services Task Force has issued a new draft guideline, with a "C" recommendation that men aged 55-69 yr should be informed about the benefits and harms of screening for prostate cancer, and offered prostate-specific antigen testing if they choose it. For men aged ≥70 yr, the recommendation remains "D", or "do not screen." This draft represents substantial progress in the right direction towards offering men a fair opportunity to discuss the risks and benefits of screening with their primary care providers. However, the evidence review underlying the draft remains fundamentally inadequate, leading to biased presentations of both benefits and harms of screening. The final guideline and future revisions should reflect formal engagement with subject matter experts to optimize the advise given to men and their physicians.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Cooperberg MR. The New US Preventive Services Task Force "C" Draft Recommendation for Prostate Cancer Screening. Eur Urol. 2017. PMID: 28535948. doi:10.1016/j.eururo.2017.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。